UNSPSC 51161718: Pentetrazol

This classification denotes a convulsant and gaba antagonist with the molecular formula C6H10N4, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier WM5Z385K7T, chemically known as 7,8,9,10-tetrazabicyclo(5.3.0)-8,10-decadiene but generally known as pentetrazol, which bears US NIH Compound Identifier 5917. European Medicines Agency schedules Pentetrazol in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB09690MIG.

UNSPSC 51161718 Pentetrazol is a Commodity code that captures pharmaceutical procurement by state and local government bodies, though the recent opportunities tagged under it show a broader pattern of pharmacy services and generic pharmaceutical supply management rather than pentetrazol specifically. State and local procurement under this code spans on-site pharmacy service provision for employee health plans, naloxone and drug deactivation systems for community health initiatives, generic multi-source pharmaceutical supply agreements, and direct-to-manufacturer prescription programs. Issuing bodies include county health departments and family health centers (Seminole County, Florida and Hall County, Georgia), state health and human services agencies (Texas HHS Commission), and cooperative purchasing alliances serving multi-state public sector clients (Minnesota Multistate Cooperative Purchasing Alliance). The work ranges from managing formularies and dispensing operations for defined employee populations to securing bulk pharmaceutical supplies through authorized wholesaler networks.

Recent activity concentrates in Florida, Georgia, Texas, and Minnesota. Seminole County, Florida issued IFB 60459723LAS in June 2026 (due July 26, 2023) for 1,900 units of naloxone and 800 safe drug deactivation systems annually with quarterly deliveries to the Seminole County Community Health Building. Hall County, Georgia released RFQ/P #47-010 (due June 4, 2026) for a single on-site pharmacy services provider to serve approximately 3,005 county employees and retirees, with scoring weighted 80 percent technical qualifications and 20 percent cost, initial term January 1, 2027 with four one-year renewal options. The Texas HHS Commission issued RFI HHS0017013 (April 3, 2026) to gather vendor capabilities for a Therapeutic Pharmacy Initiative Direct-to-Manufacturer Prescriptions program, functioning as exploratory market research ahead of formal procurement. The Minnesota Department of Administration's Office of State Procurement, administering MMCAP, released an RFP due March 26, 2026 for generic multi-source pharmaceuticals and OTC products to be distributed through AmerisourceBergen, Cardinal Health, and Morris & Dickson, with 75 percent scoring weight on price competitiveness and contract effectiveness July 1, 2026.